

Supporting information

A Detailed Study of the Intramolecular Hydroamination of *N*-(*ortho*-alkynyl)aryl-*N'*-Substituted Trifluoroacetamidines and Bromodifluoroacetamidines

Jiangtao Zhu,^a Haibo Xie,^a Zixian Chen,^a Shan Li,^a Yongming Wu^{a,*}

^a Key laboratory of Organofluorine Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, 345 Lingling Road, Shanghai 200032, China
Fax: (+86) 21-64166128. E-mail: ymwu@mail.sioc.ac.cn


Table of contents

General information	S1
Experimental Procedure for the synthesis of 2	S2-S8
NMR spectra for compounds	S9-S39
X-ray for compounds 3j , 4j' and 4e	S39-S40

General:


Melting points were measured on a Melt-Temp apparatus and uncorrected. ¹H NMR spectra were recorded in CDCl₃ on a Bruker AM-300 spectrometer (300 MHz) with TMS as internal standard. ¹³C NMR spectra were taken on a Bruker AM-400 (100 MHz) spectrometer. IR spectra were obtained with a Nicolet AV-360 spectrophotometer. Elemental analysis was performed by the Analytical Laboratory of Shanghai Institute of Organic Chemistry. Mass spectra were recorded by EI methods. HRMS (EI) was measured on Waters Micromass GCT Premier mass spectrometer. Solvents and reagents were purchased from commercial sources and used as received. Flash column chromatography was carried out using 300-400 mesh silica gel at increased pressure and petroleum ether/ethyl acetate combination was used as the eluent.

1. Synthesis of **2** from the corresponding acetimidoyl chloride and amine.




A 50 mL flask was charged fluorinated acetimidoyl chloride **1** (6 mmol), the corresponding amine (7.2 mmol), triethylamine (727 mg, 7.2 mmol), DMF (20 mL). The resulting mixture was stirred at 80 °C for 2 h. Water (10 mL) was added to the mixture, which was then extracted with ethyl acetate (20 mL × 3). The combined organic layers were washed by saturated salt water, dried over MgSO₄ and concentrated in vacuo, giving a residue which was subjected to silica gel chromatography to furnish the pure product **2**.

N-Benzyl-2,2,2-trifluoro-*N'*-(2-(phenylethyynyl)phenyl)acetimidamide (**2a**)



¹H NMR (300 MHz, CDCl₃): δ 7.81 – 6.61 (m, 14H), 5.26 (brs, 1H), 4.47 (brs, 2H); MS (EI): m/z (%): 278 (20.83) [M⁺], 91 (100.00); Anal. Calcd. for C₂₃H₁₇F₃N₂: C, 73.01; H, 4.53; N, 7.40; Found: C, 72.94; H, 4.65; N, 7.25; IR (film): ν 3426, 3063, 3030, 1680, 1530, 1493, 1206, 1148, 754 cm⁻¹.


2,2,2-trifluoro-*N'*-(2-(phenylethyynyl)phenyl)acetimidamide (**2b**)



¹H NMR (300 MHz, CDCl₃): δ 7.67 – 7.23 (m, 7H), 7.11 (t, J = 7.6 Hz, 1H), 6.96 (d, J = 7.9 Hz, 1H), 4.92 (brs, 2H); MS (EI): m/z (%): 288 (61.40) [M⁺], 193 (100.00); HRMS (EI) Calcd. for C₁₆H₁₁F₃N₂: 288.0874, Found: 288.0880; IR (film): ν 3464, 3388, 3323, 3160, 1681, 1593, 1493,


1424, 1209, 1166, 754 cm^{-1} .

N-Cyclohexyl-2,2,2-trifluoro-*N'*-(2-(phenylethynyl)phenyl)acetimidamide (**2d**)




^1H NMR (300 MHz, CDCl_3): δ 7.82 – 6.34 (m, 9H), 4.88 (brs, 1H), 3.67 (brs, 1H), 2.31 – 1.80 (s, 2H), 1.80 – 0.93 (m, 8H); MS (EI): m/z (%): 370 (49.84) [M^+], 288 (100.00); HRMS (EI) Calcd. for $\text{C}_{22}\text{H}_{21}\text{F}_3\text{N}_2$: 370.1657, Found: 370.1658; IR (film): ν 3285, 2922, 2851, 1655, 1544, 1187, 1151, 752 cm^{-1} .

2,2,2-Trifluoro-*N*-(4-methoxyphenyl)-*N'*-(2-(phenylethynyl)phenyl)acetimidamide (**2e**)




^1H NMR (300 MHz, CDCl_3): δ 8.85 – 6.10 (m, 14H), 3.73 (s, 3H); MS (EI): m/z (%): 394 (8.08) [M^+], 204 (100.00); Anal. Calcd. for $\text{C}_{23}\text{H}_{17}\text{F}_3\text{N}_2\text{O}$: C, 70.04; H, 4.34; N, 7.10; Found: C, 70.21; H, 4.32; N, 7.06; IR (film): ν 3383, 3057, 2851, 1668, 1510, 1243, 1147, 1033, 754 cm^{-1} .

2,2,2-Trifluoro-*N*-(4-nitrophenyl)-*N'*-(2-(phenylethynyl)phenyl)acetimidamide (**2g**)




^1H NMR (300 MHz, CDCl_3): δ 8.54 – 6.61 (m, 14H); MS (EI): m/z (%): 409 (100.00) [M^+]; Anal. Calcd. for $\text{C}_{22}\text{H}_{14}\text{F}_3\text{N}_3\text{O}$: C, 64.55; H, 3.45; N, 10.26; Found: C, 64.73; H, 3.54; N, 10.23; IR (film): ν 3377, 1682, 1580, 1541, 1508, 1337, 1163, 1128, 754 cm^{-1} .

N-benzyl-*N'*-(2-((4-chlorophenyl)ethynyl)phenyl)-2,2,2-trifluoroacetimidamide (**2h**)




¹H NMR (300 MHz, CDCl₃): δ 7.68 – 6.62 (m, 13H), 5.29 (brs, 1H), 4.46 (brs, 2H); MS (EI): m/z (%): 412 (15.32) [M⁺], 91 (100.00); HRMS (EI) Calcd. for C₂₃H₁₆ClF₃N₂: 412.0954; Found: 421.0955; IR (film): ν 3426, 3057, 3030, 1678, 1530, 1493, 1207, 1147, 828, 751 cm⁻¹.

N-Benzyl-2,2,2-trifluoro-*N'*-(2-(p-tolyethyl)phenyl)acetimidamide (**2i**)




¹H NMR (300 MHz, CDCl₃): δ 7.59 – 6.71 (m, 13H), 5.25 (brs, 1H), 4.43 (brs, 2H), 2.36 (s, 3H); MS (EI): m/z (%): 392 (2.52) [M⁺], 204 (100.00); Anal. Calcd. for C₂₄H₁₉F₃N₂: C, 73.46; H, 4.88; N, 7.14; Found: C, 73.53; H, 4.89; N, 7.07; IR (film): ν 3426, 3068, 3035, 2927, 1681, 1526, 1510, 1207, 1147, 816, 750 cm⁻¹.

N-Benzyl-2-bromo-2,2-difluoro-*N'*-(2-(phenylethynyl)phenyl)acetimidamide (**2j**)




¹H NMR (300 MHz, CDCl₃): δ 7.60 – 6.87 (m, 14H), 5.22 (brs, 1H), 4.39 (brs, 2H); MS (EI): m/z (%): 438 (6.97) [M⁺], 91 (100.00); Anal. Calcd. for C₂₃H₁₇BrF₂N₂: C, 62.88; H, 3.90; N, 6.38; Found: C, 63.08; H, 3.92; N, 6.34; IR (film): ν 3426, 3063, 3052, 1673, 1520, 1493, 1170, 1110, 919, 857, 754 cm⁻¹.

2-Bromo-*N*-butyl-2,2-difluoro-*N'*-(2-(phenylethynyl)phenyl)acetimidamide (**2k**)




¹H NMR (300 MHz, CDCl₃): δ 7.50 – 6.87 (m, 9H), 4.93 (brs, 1H), 3.14 (brs, 2H), 1.49 (brs, 2H), 1.29 – 1.24 (m, 2H), 0.82 (t, J = 6.9 Hz, 3H); MS (EI): m/z (%): 404 (4.22) [M⁺], 187 (100.00); HRMS (EI) Calcd. for C₂₀H₁₉BrF₂N₂: 404.0700, Found: 404.0702; IR (film): ν 3421, 3057, 2959, 2932, 2862, 1673, 1523, 1493, 1174, 1112, 911, 755 cm⁻¹.

2-Bromo-N-cyclohexyl-2,2-difluoro-N'-(2-(phenylethynyl)phenyl)acetimidamide (2l)




¹H NMR (300 MHz, CDCl₃): δ 7.50 – 6.87 (m, 9H), 4.83 (brs, 1H), 3.46 (brs, 1H), 1.99 (brs, 2H), 1.64 – 1.10 (m, 8H); MS (EI): m/z (%): 430 (31.10) [M⁺], 98 (100.00); Anal. Calcd. for C₂₂H₂₁BrF₂N₂: C, 61.26; H, 4.91; N, 6.49; Found: C, 61.40; H, 4.95; N, 6.45; IR (film): ν 3415, 3046, 2931, 2854, 1668, 1515, 1493, 1472, 1170, 1110, 896, 754 cm⁻¹.

N-Allyl-2-bromo-2,2-difluoro-N'-(2-(phenylethynyl)phenyl)acetimidamide (2m)




¹H NMR (300 MHz, CDCl₃): δ 7.78 – 6.63 (m, 9H), 5.84 (brs, 1H), 5.40 – 4.75 (m, 3H), 3.83 (brs, 2H); MS (EI): m/z (%): 388 (43.08) [M⁺], 254 (100.00); HRMS (EI) Calcd. for C₁₉H₁₅BrF₂N₂: 388.0387, Found: 388.0393; IR (film): ν 3421, 3057, 3019, 1673, 1518, 1493, 1473, 1174, 1112, 924, 755 cm⁻¹.

2-Bromo-2,2-difluoro-N-(4-methoxyphenyl)-N'-(2-(phenylethynyl)phenyl)acetimidamide (2n)




¹H NMR (300 MHz, CDCl₃): δ 9.14 – 6.28 (m, 14H), 4.00 (s, 3H); MS (EI): m/z (%): 454 (26.09) [M⁺], 375 (100.00); Anal. Calcd. for C₂₃H₁₇BrF₂N₂O: C, 60.67; H, 3.76; N, 6.15; Found: C, 60.96; H, 3.93; N, 6.10; IR (film): ν 3388, 3063, 2829, 1673, 1582, 1510, 1442, 1240, 1146, 754 cm⁻¹.

N-Benzyl-2-bromo-2,2-difluoro-*N'*-(2-(hex-1-yn-1-yl)phenyl)acetimidamide (**2o**)




¹H NMR (300 MHz, CDCl₃): δ 7.51 – 6.55 (m, 9H), 5.06 (brs, 1H), 4.23 (brs, 2H), 2.51 – 2.01 (m, 2H), 1.71 – 1.10 (m, 4H), 0.84 (t, J = 5.7 Hz, 3H); MS (EI): m/z (%): 418 (3.57) [M⁺], 91 (100.00); HRMS (EI) Calcd. for C₂₁H₂₁BrF₂N₂: 418.0856, Found: 418.0858; IR (film): ν 3421, 3068, 3053, 2954, 2932, 2873, 1674, 1520, 1477, 1171, 1116, 917, 749 cm⁻¹.

2-Bromo-2,2-difluoro-*N'*-(2-(hex-1-yn-1-yl)phenyl)-*N*-(4-methoxyphenyl)acetimidamide (**2p**)




¹H NMR (300 MHz, CDCl₃): δ 7.64 – 5.87 (m, 9H), 3.73 (s, 3H), 2.68 – 2.21 (m, 2H), 1.81 – 1.37 (m, 4H), 1.11 – 0.68 (m, 3H); MS (EI): m/z (%): 434 (17.06) [M⁺], 355 (100.00); Anal. Calcd. for C₂₁H₂₁BrF₂N₂O: C, 57.94; H, 4.86; N, 6.44; Found: C, 58.09; H, 4.95; N, 6.39; IR (film): ν 3383, 2954, 2927, 1668, 1504, 1240, 1147, 1085 cm⁻¹.

N-Benzyl-2-bromo-2,2-difluoro-*N'*-(2-((4-methoxyphenyl)ethynyl)phenyl)acetimidamide (**2q**)




¹H NMR (300 MHz, CDCl₃): δ 7.63 – 6.60 (m, 13H), 5.20 (brs, 1H), 4.39 (brs, 2H), 3.83 (s, 3H); MS (EI): m/z (%): 468 (10.48) [M⁺], 91 (100.00); Anal. Calcd. for C₂₄H₁₉BrF₂N₂O: C, 61.42; H, 4.08; N, 5.97; Found: C, 61.69; H, 4.14; N, 5.94; IR (film): ν 3431, 3068, 3035, 2927, 2829, 1673, 1605, 1510, 1474, 1248, 1173, 1108, cm⁻¹.

2-Bromo-N-butyl-N'-(2-ethynylphenyl)-2,2-difluoroacetimidamide (2s)




¹H NMR (300 MHz, CDCl₃): δ 7.44 – 6.84 (m, 4H), 4.93 (brs, 1H), 3.18 (s, 1H), 3.15 – 3.12 (m, 2H), 1.60 – 0.80 (m, 7H); MS (EI): m/z (%): 328 (30.58) [M⁺], 116 (100.00); HRMS (EI) Calcd. for C₁₄H₁₅BrF₂N₂: 328.0387; Found: 328.0381;

N-Benzyl-2-bromo-N'-(2-ethynylphenyl)-2,2-difluoroacetimidamide (2r)




¹H NMR (300 MHz, CDCl₃): δ 7.44 – 6.84 (m, 9H), 5.24 (brs, 1H), 4.37 (brs, 2H), 3.19 (s, 1H); MS (EI): m/z (%): 362 (0.96) [M⁺], 91 (100.00); HRMS (EI) Calcd. for C₁₇H₁₃BrF₂N₂: 362.0230; Found: 362.0228; IR (film): ν 3426, 3298, 3063, 3019, 2103, 1673, 1591, 1521, 1475, 1170, 1114, 917, 849, 750 cm⁻¹.

2-Bromo-N-cyclohexyl-N'-(2-ethynylphenyl)-2,2-difluoroacetimidamide (2t)





¹H NMR (300 MHz, CDCl₃): δ 7.44 – 6.84 (m, 4H), 4.80 (brs, 1H), 3.17 (s, 1H), 2.01-1.13 (m, 11H); MS (EI): m/z (%): 354 (4.50) [M⁺], 55 (100.00); HRMS (EI) Calcd. for C₁₆H₁₇BrF₂N₂: 345.0543; Found: 345.0541; IR (film): ν 3415, 3310, 2932, 2855, 2018, 1670, 1592, 1518, 1474, 1171, 1113, 896 cm⁻¹.

N-Allyl-2-bromo-*N'*-(2-ethynylphenyl)-2,2-difluoroacetimidamide (**2u**)




¹H NMR (300 MHz, CDCl₃): δ 7.44 – 6.80 (m, 4H), 5.85 (brs, 1H), 5.21 – 5.14 (m, 3H), 3.82 (brs, 2H), 3.19 (s, 1H); MS (EI): m/z (%): 312 (36.27) [M⁺], 115 (100.00); HRMS (EI) Calcd. for C₁₃H₁₁BrF₂N₂: 312.0074; Found: 312.0076; IR (film): ν 3428, 3301, 3063, 2911, 2097, 1676, 1522, 1475, 1174, 924 cm⁻¹.


3a




3b





3c







3d







3e







3f







3g







3h







3i







3j







3k







3l







3m







3n







3o







3p







3q







3r







3s







3t







3u







3v







4j'







4e







6a







6b







6c







6d







3w






3x





3y







Figure 1. X-Ray Crystal Structure of **3j**




Figure 2. X-Ray Crystal Structure of **4j'**




Figure 3. X-Ray Crystal Structure of **4e**